https://www.thebodypro.com/category/raltegravir-isentress-mk0518/tag/conference-coverage
Raltegravir (Isentress)

Conference Coverage

The Latest

pregnant woman talking to doctor

Raltegravir Not Linked to Birth Defects, Study Shows

Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.

Pair of female feet on a bathroom scale

One Class of HIV Drugs Is Associated With Weight Gain. What's the Latest?

The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants Img

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants

Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.

Raltegravir-Based Third-Line ART in Children and Adolescents Img

Raltegravir-Based Third-Line ART in Children and Adolescents

Five case studies from Uganda showed good responses in children and adolescents receiving raltegravir-based third-line ART.

Raltegravir in HIV-Exposed Neonates Img

Raltegravir in HIV-Exposed Neonates

Daily raltegravir was well tolerated and met pharmacokinetic targets in full term HIV-exposed infants at high risk of infection, in a study presented at the 8th International Workshop on HIV Paediatrics.

Once-Daily Raltegravir and Dolutegravir-Based Dual-Drug Regimen Show Promise Img

Once-Daily Raltegravir and Dolutegravir-Based Dual-Drug Regimen Show Promise

On behalf of IFARA, Fred Schaich spoke with Pedro Cahn, M.D., Ph.D., about two late-breaking studies presented at this year's International AIDS Conference and about global funding for HIV.

Once-Daily Raltegravir at Last Available: Week 48 Results From ONCEMRK Study Img

Once-Daily Raltegravir at Last Available: Week 48 Results From ONCEMRK Study

After many years of research, Merck now have a once-daily formulation of raltegravir -- though it requires two tablets with a higher milligram dose.

Promising Results for New, Simpler Dosing of Raltegravir (Isentress) Img

Promising Results for New, Simpler Dosing of Raltegravir (Isentress)

The ONCEMRK study compared a new once-a-day dosing of raltegravir to the current twice-a-day dosing schedule. This simplification could help individuals improve adherence to their regimens which may result in better suppression of HIV over time.

Pharmacokinetics of Antiretrovirals in Pregnancy: Rilpivirine, Etravirine and Raltegravir Img

Pharmacokinetics of Antiretrovirals in Pregnancy: Rilpivirine, Etravirine and Raltegravir

Three posters at CROI 2015 described pharmacokinetics of antiretrovirals in pregnancy for rilpivirine, etravirine and raltegravir. None of the studies suggested that dose adjustment is required.

Significantly Less BMD Loss With HIV Therapy That Doesn't Contain Tenofovir/Emtricitabine Img

Significantly Less BMD Loss With HIV Therapy That Doesn't Contain Tenofovir/Emtricitabine

Raltegravir was associated with significantly less bone mineral density (BMD) loss in the hip and lumbar spine than was tenofovir/emtricitabine when used as part of a first-line antiretroviral therapy regimen that contained darunavir boosted with rit...